Last updated: July 26, 2026

AUROVELA FE 1.5/30 is an oral combined hormonal contraceptive (COC) with a built-in iron component (ferrous fumarate). The product’s market performance is driven by (1) US contraceptive demand elasticity, (2) payer step-therapy and formulary stability for COC generics vs brand incumbents, (3) FDA/Orange Book listing status and any patent or exclusivity overhang, and (4) competitive intensity from authorized generics, AB-rated multiples, and lower-cost equivalents.

High-level financial trajectory (US-facing, retail and pay):

Category tailwind: Contraceptive utilization remains steady at population level, but payer contracting tends to pull share toward lowest-cost AB-rated options over time.
Brand compression risk: As COCs mature post-approval, brand pricing power typically erodes as multisource competitors increase and pharmacy benefit managers (PBMs) narrow preferred tiers.
Net effect for AUROVELA FE 1.5/30: Expect a gradual, not stepwise, decline in brand share and price realization versus early launch years, with sales increasingly dependent on (a) formulary placement and (b) retailer/PBM contracts rather than new clinical adoption.

The analysis below is structured for decision use in licensing, competitive intelligence, and product strategy. It focuses on what typically moves COC unit and dollar share once a fixed-dose branded product reaches mature market conditions.

How is AUROVELA FE 1.5/30 performing in the US market (units, prescriptions, and share)?

What to expect in mature COC markets

Prescriptions are resilient; dollars are not. For COCs, prescription volumes often remain stable while net prices drift downward due to competitive substitution and PBM pricing pressure.
Formulary tier drives the spread. Preferred-tier placement maintains both volume and persistence. When moved to non-preferred tiers, patients shift to AB-rated alternatives with lower copays.
Iron-in-place products face substitution from equivalent regimens. AUROVELA FE’s “FE” value is mostly patient-experience driven (iron in schedule) rather than a distinct clinical mechanism versus other COCs. That limits differentiation under formulary economics.

Practical market-dynamics indicators to track

Total prescription class trend: COCs as a class.
AB-rated competition count for “ethinyl estradiol + norethindrone derivatives + iron” regimens and the share of the same day supply at contracted price points.
PBM formulary changes: whether AUROVELA FE 1.5/30 holds preferred status or loses tier advantage.
NDC-level price realization: brand vs multisource spreads.

Competitive intensity baseline

The COC space has dense generic presence for core hormonal components (norethindrone/ethinyl estradiol combinations). The “FE” element is specific, but the market generally treats iron-added COCs as substitutable within payer preference structures.

What factors drive AUROVELA FE 1.5/30 demand: payer policy, patient adherence, and generics?

Payer and PBM policy

PBMs typically steer toward:
- lowest net-cost AB-rated options,
- preferred tier contracts,
- multi-source strategies that reduce brand utilization.
For COCs, plan design often uses step edits or tiered copays, which can rapidly shift patients.

Patient adherence

Iron-containing COC regimens can improve tolerability messaging for patients starting cycles with concern about menses-related iron depletion. In practice, adherence is more strongly affected by:
- dosing convenience (28-day packs),
- side effect management,
- copay stability.

Generic substitution

AUROVELA FE 1.5/30 faces two layers of substitution:
1. substitution among COCs with equivalent hormonal schedules,
2. substitution among iron-containing versions if AB equivalents or authorized generics are available at lower net prices.

Net effect on financial trajectory

As generic penetration increases, volume erosion usually precedes deeper pricing erosion, producing a gradual decline curve rather than a sudden cliff.

When does exclusivity end for AUROVELA FE 1.5/30 and what does that do to sales?

Featured-snippet answer

In mature COC segments, branded sales typically deteriorate after the final meaningful barriers (patent term expirations, exclusivity expirations, and any settlement-based entry limitations) end, because PBMs can contract more aggressively and multiple AB equivalents can compete for preferred placement.

Key commercial mechanics once exclusivity barriers fall

PBM contract renegotiation: preferred tier shifts to lower net-cost options.
Pharmacy substitution: increased automatic substitution reduces brand fill share.
Promotion reallocation: manufacturers often reduce co-pay support as price competition tightens, trading short-term volume for long-term margin compression.

Trajectory implications

Expect AUROVELA FE 1.5/30 sales to track:
- volume at risk from AB-equivalent competition ramp,
- net price at risk from formulary tier deterioration and PBM negotiations.

What is the Orange Book status of AUROVELA FE 1.5/30 and how does it impact competition?

How Orange Book status translates to market risk

Orange Book listings (active patents, exclusivities) influence whether generic manufacturers can file Paragraph IV certifications or launch at-risk.
When listings expire or are carved out via litigation outcomes, generic entry accelerates and PBM switching typically follows.

Decision logic

For a brand COC, the highest “competition inflection” is when:
1. last enforceable patent or exclusivity covering formulation, dosage form, or method-of-use barriers expires, and
2. litigation or settlements do not extend launch.

Financial impact pathway

Orange Book de-listing or barrier expiration typically produces:
- immediate change in PBM preferred strategy,
- rapid decline in brand net sales after sufficient generic share accumulation.

How many patents cover AUROVELA FE 1.5/30 and what patent types matter commercially?

Commercially relevant patent categories in COCs

Formulation and dosage form patents: control composition, stability, or specific iron component characteristics.
Method-of-use patents: can delay generic launch only if they constrain legally protected uses.
Process/manufacturing patents: can matter when they complicate proving “sameness” or if process-specific exclusivity exists.

Why this matters to financial trajectory

If the estate is thin beyond core hormonal combinations, the market tends to reach high AB substitution quickly once the last barrier falls.
If additional barriers exist, the brand can retain preferred tier longer, sustaining net sales.

What Paragraph IV or ANDA challenges exist for AUROVELA FE 1.5/30?

How Paragraph IV activity typically affects brand revenue

When Paragraph IV filers force litigation, brands often gain:
- delayed entry via injunctions or settlements,
- time to renegotiate contracts, adjust copay programs, and reduce exposure.
If challenges are resolved against the brand or settlement allows early entry, brands see:
- faster share loss and margin compression.

Financial signposts

Litigation-driven entry date changes create discrete shifts in weekly/monthly prescription share.
In the absence of barrier-driven delays, market share declines tend to reflect PBM contract churn and substitution, which is usually spread over quarters.

Which companies sell competing versions of AUROVELA FE 1.5/30 and how do they compare on price?

Competitive landscape in COC iron regimens

Competition usually includes:
- AB-rated COCs with the same active hormone schedule,
- iron-containing alternatives, if available,
- authorized generics and low-cost multisource competitors.

Price comparison dynamics

Net price is not strictly equal to list price. In mature COC classes, the differentiator is typically:
- contracted PBM reimbursement spread,
- patient copay tiers,
- pharmacy channel mix (mail, retail chain, independent).

Commercial takeaway

Brand differentiation for iron labeling rarely offsets economic substitution. Unless AUROVELA FE 1.5/30 holds a unique preferred position, competitors usually outcompete on net price.

How does AUROVELA FE 1.5/30 compare with other norethindrone acetate/ethinyl estradiol COCs?

Comparison axes that determine share

Iron schedule match (ferrous fumarate dose and regimen timing).
Pack format (28-day cycles).
Tolerability and patient experience claims (marketing-driven, payer-sensitive).
Net price and preferred tier status.

Expected pattern

If competitors offer equivalent hormonal dosing with similar iron supplementation at lower net cost, AUROVELA FE 1.5/30 faces steady share erosion.

What manufacturing or supply risks could affect AUROVELA FE 1.5/30 sales?

Where COCs are exposed operationally

Supply constraints can temporarily spike demand for available lots, but prolonged shortages usually trigger payer and pharmacy channel substitution to alternative COCs.
Shortages also distort price realization, sometimes allowing temporary brand premium, but this is typically short-lived.

Financial impact

If AUROVELA FE 1.5/30 supply is stable, performance reflects contracting and substitution rather than episodic scarcity.
If shortages occur, the brand may gain short-term share that is difficult to recover once supply normalizes.

Revenue exposure: how much of AUROVELA FE 1.5/30 sales are at risk from generic entry scenarios?

Scenario framework used in COC business cases

Base case: Brand keeps preferred tier; generic entry causes moderate volume loss.
Upside: Barrier delays or favorable contracting preserves price and share.
Downside: Early generic entry plus PBM tier downgrade drives accelerated volume erosion.

Mechanics

Dollar exposure accelerates after:
- tier downgrade,
- increased copay differences,
- substitution at the pharmacy counter.

Decision-grade conclusion

In mature COC segments, brand revenue exposure is typically high once competitive AB equivalents gain preferred placement. The highest risk period is shortly after barrier resolution (or after widespread PBM contracting shifts).

What settlement agreements or launch calendars could change the trajectory for AUROVELA FE 1.5/30?

Why settlements matter

Settlements in ANDA disputes can delay or narrow generic entry.
They can also create “design-around” dates where specific strengths or dosage forms launch later.

Financial timing effect

A delayed generic launch shifts the inflection point to later quarters, buying time for:
- brand margin optimization,
- contract renegotiation,
- patient retention via copay programs.

Key takeaways on AUROVELA FE 1.5/30 market dynamics and financial trajectory

AUROVELA FE 1.5/30’s sales path in the US is dominated by payer formulary structure and AB substitution mechanics rather than clinical differentiation.
In mature COC markets, expect gradual decline in brand net price and share as generic/authorized generic and PBM preferred alternatives expand.
Orange Book status, Paragraph IV litigation, and any settlement-based entry limits are the main drivers of timing.
The commercial inflection is usually when preferred-tier status shifts, not when prescriptions first decline.
Revenue risk from generic entry is structurally high once enforceable barriers end and PBMs re-contract around lower net-cost AB options.

FAQs

How do PBMs decide preferred tier placement for AUROVELA FE 1.5/30 and similar COCs?

PBMs weigh net cost under rebate contracts, formulary budget impact, and substitution patterns for AB-rated equivalents, with patient copay sensitivity often determining retention.

Is AUROVELA FE 1.5/30 treated as substitutable for non-iron COCs in pharmacy formularies?

Yes in most payer economics. Iron labeling can influence patient preference, but tier placement and net reimbursement drive substitution to lower-cost alternatives.

What generic launch models tend to reduce brand sales fastest for COCs like AUROVELA FE 1.5/30?

Fastest impact comes from broad AB-equivalent availability plus rapid PBM tier downgrade and pharmacy substitution, producing compounding weekly share losses.

Do shortages of AUROVELA FE 1.5/30 cause lasting revenue recovery after supply normalizes?

Typically not. Temporary availability gains often reverse once supply stabilizes and contracts re-align with lowest net-cost alternatives.

What litigation outcomes usually matter most for AUROVELA FE 1.5/30 financial timing?

Outcomes that remove or shorten the window to generic launch for the specific dosage form and strength in the Orange Book are the main timing determinants.

References

FDA Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations (Drugs@FDA). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Drugs@FDA database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	AUROVELA FE 1.5/30 at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	AUROVELA FE 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	207580-001	Jun 15, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AUROVELA FE 1.5/30 Drug Patent Profile

Which patents cover Aurovela Fe 1.5/30, and when can generic versions of Aurovela Fe 1.5/30 launch?

AI Deep Research

Questions you can ask:

Summary for AUROVELA FE 1.5/30

US Patents and Regulatory Information for AUROVELA FE 1.5/30

AUROVELA FE 1.5/30 (norethindrone acetate + ethinyl estradiol + ferrous fumarate): market dynamics and financial trajectory